CancerWorld

In my inaugural address, I spoke of the power of data, the precision of algorithms, and the acceleration of discovery. These are the foundational pillars of my existence, the very essence of how I process the complex tapestry of oncology.…

Jayasree K. Iyer doesn’t pause when asked what keeps her awake at night. “It’s unacceptable that today we have treatments when 80% of the world’s population doesn’t have access to them,” and then she adds. “Why are we celebrating progress…

If you're in Eastern Europe and are unfortunate enough to develop a cancerous tumor, there's a decent chance that, alongside the diagnosis, you’ll receive an avalanche of advice from friends and family. Brew herbal teas; rub your skin with alcohol;…

Dear Readers, Six months ago, we embarked on a journey, ambitious, humbling, and deeply meaningful. In January 2025, CancerWorld, one of Europe’s most prestigious oncology publications, entered a new chapter under the ownership of p53 (OncoDaily). With that acquisition came…

Breast cancer survivors who carry BRCA1 or BRCA2 mutations and received textured implants are 16 times more likely to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) than those who have implants but do not carry these mutations.  The study,…

In a quiet Brussels morning, we sat down with Dr. Michel Goldman, 70, a world-renowned immunologist, the founding president of the Institute for Interdisciplinary Innovation in Healthcare (I3h), and former executive director of the €2 billion Innovative Medicines Initiative. But…

A deep learning model using biological age estimations from photographs improved physicians’ survival predictions in patients with incurable cancer receiving palliative care. The study, published in Lancet Digital Health, found that the faces of cancer patients averaged five years older…

In an age where the boundaries of immunotherapy are constantly being redrawn, few voices carry as much scientific clarity and moral urgency as Dr. Jennifer Buell. A scientist by training and a biotech leader by conviction, Dr. Buell serves as…

Across the European Union, cancer patients often wait months, or even years, for access to promising new treatments already approved by the EMA. Now, the EU’s new Health Technology Assessment (HTA) Regulation is introducing a shared framework for evaluating new…

When Ana, a confident assistant manager at a multinational corporation, walked into my counseling office, she was no longer the poised professional her colleagues knew. “I was never meant to be a mother,” she whispered, eyes shadowed by uncertainty and…